Investment
Features
FeesSafety
Academy
More
Pluang+

JD Sports cuts profit forecast after weak sales, shares drop nearly 15%.

Analyst Insights
21 Aug 2026
Danny Green
View Source
Bearish
pluang ai news

JD Sports Fashion reported weaker-than-expected second-quarter sales, especially in North America, prompting a cut in its full-year profit guidance. This led to a nearly 15% drop in its stock price. Analysts from Citigroup, UBS, and Shore Capital maintained cautious ratings, with Shore Capital lowering profit forecasts by up to 10%. Despite the challenges, Citigroup raised its price target slightly, reflecting a mixed outlook for the retailer's near-term performance.

More News

PDD Holdings set to report Q2 earnings with mixed analyst outlook and strong financial health.

PDD Holdings set to report Q2 earnings with mixed analyst outlook and strong financial health.

PDD Holdings Inc. will report its Q2 2026 earnings on August 24, with expected EPS of $2.72 and revenue around $16.94 billion. Despite recent stock gains, analysts have mixed views, including an Underperform rating from BNP Paribas and a downgrade by...

Company Fundamentals
Neutral
25 minutes ago
Jones Lang LaSalle sees insider sale but strong institutional buying and bullish golden cross signal.

Jones Lang LaSalle sees insider sale but strong institutional buying and bullish golden cross signal.

Jones Lang LaSalle's CEO sold 2,000 shares worth over $773,000, yet major investors like BlackRock increased holdings significantly, showing confidence. BlackRock now owns over 10% of the company after a $1.45 billion stake purchase. Other firms also...

Market News
Bullish
1 hour ago
Wedbush raises Scholar Rock price target to $64 ahead of FDA decision on SMA drug.

Wedbush raises Scholar Rock price target to $64 ahead of FDA decision on SMA drug.

Wedbush increased its price target for Scholar Rock to $64 from $58 and kept an "Outperform" rating ahead of the FDA's September 30 decision on Scholar Rock's investigational SMA drug, apitegromab. This drug could be the first muscle-targeted therapy...

Analyst Insights
Bullish
2 hours ago
IM Cannabis to execute 1-for-30 reverse stock split to meet Nasdaq's $1 minimum share price

IM Cannabis to execute 1-for-30 reverse stock split to meet Nasdaq's $1 minimum share price

IM Cannabis Corp., a medical cannabis company operating in Israel and Germany, will conduct a 1-for-30 reverse stock split on August 27, 2026. This move aims to increase its share price, currently at $0.11, to meet the Nasdaq Capital Market's minimum...

Company Fundamentals
Neutral
3 hours ago
Buckle posts strong Q2 with EPS $0.87 and revenue $319.82M, beating estimates despite slight net income dip.

Buckle posts strong Q2 with EPS $0.87 and revenue $319.82M, beating estimates despite slight net income dip.

Buckle, Inc. reported strong Q2 earnings with an EPS of $0.87, surpassing analyst estimates of $0.81, and revenue of $319.82 million, slightly above expectations. The company saw a 4.6% increase in net sales, driven by growth in both comparable-store...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App